Skip to Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

NCI Formulary
Contact NExT
Show menu
Search this site
Last Updated: 04/06/20

Information below provided by the Pharmaceutical Company.

Selpercatinib (LOXO-292)

Agent Description

Selpercatinib is an investigational selective RET inhibitor being studied for the treatment of RET fusion-positive cancers across tumor types and RET-mutated medullary thyroid cancer (MTC).

Mechanism of Action

Selpercatinib binds to the ATP-binding site of the RET kinase, preventing it from downstream signaling.

Classification

Selective RET inhibitor

Molecular Targets

RET

Monograph

Selpercatinib has Breakthrough Therapy Designation in three indications:

  • For the treatment of patients with metastatic RET-fusion positive NSCLC who require systemic therapy and have progressed following platinum-based chemotherapy and an anti-PD-1 or anti-PD-L1 therapy.
  • For the treatment of patients with RET-mutant MTC who require systemic therapy, have progressed following prior treatment and have no acceptable alternative treatment options.
  • For the treatment of patients with advanced RET fusion-positive thyroid cancer who require systemic therapy, have progressed following prior treatment and have no acceptable alternative treatment options.

The results of a phase 1/2 study of selpercatinib in patients with advanced solid tumors, RET fusion-positive solid tumors, and MTC have been recently presented.

A randomized, phase 3 study in treatment-na´ve RET fusion-positive NSCLC is being implemented to evaluate selpercatinib versus pemetrexed with a platinum agent with or without pembrolizumab.

A randomized, phase 3 study is being designed to evaluate selpercatinib versus cabozantinib or vandetanib (investigators choice) in kinase inhibitor-na´ve RET-mutant MTC.

Studies of Interest

  • Studies evaluating RET-fusion positive NSCLC in first line setting
  • Studies evaluating RET-mutant MTC in first line setting
  • Studies evaluating pediatric patients

Concepts that would not be supported are those that compete against ongoing or future Loxo Oncology or Lilly-sponsored studies.

Information collaborator would like included in investigator proposals

N/A